tHEORetically Speaking: Meeting the Resource Challenge - Why Biotechs Need a Different Kind of Partner

episode

tHEORetically Speaking not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from tHEORetically Speaking

From Data Access to Evidence Usability: Connecting Payer Policy, Real-World Data, and Clinical Context to Close the Evidence Gap 11 min · 13 Jul 2026

All episodes from tHEORetically Speaking →

Report any issue

Source

Recorded28 Jul 2025

Publisherfeeds.buzzsprout.com

Handlerec:11539526

Show notes

In this episode of Theoretically Speaking, Paige McGarry interviews David W. Miller, CEO of Genesis Research Group, discussing the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.David W. Miller discusses how Genesis Research Group addresses these challenges, including the importance of demonstrating value early in development, the role of real-world evidence in supporting biotechs, and how to navigate uncertainty in the biotech landscape. Additionally, strategies for effective data collection are introduced, while emphasizing the need for flexibility and adaptability in the ever-evolving life sciences sector. Genesis Research Group's Flexible Integrated Team (FIT) model is also discussed as an adaptable and fit-for-purpose program to support biotechs, ensuring development and launch are optimized, regardless of size, resources, and specific needs. Representing a true paradigm shift in strategic partnerships, David explains how the Genesis team is able to adapt their extensive global expertise in areas such as pricing, real-world evidence, HEOR, and market access as they support emerging biotechs to ensure commercial success.For more information or to access other resources, click here.Health Economics is moving fast. From value frameworks to AI driven modeling, you don't want to miss what's next. Join thousands of professionals who trust Health Economics.com as their go to resource. Subscribe for weekly insights, expert commentary, and the latest developments across HEOR and market access: https://healtheconomics.com/subscribe/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.